Acknowledgments
J.W. is supported by a Clinical Research Training Fellowship from the Cancer Research UK Cambridge Cancer Centre. Funding for the National Institute for Health Research (NIHR) BioResource Rare Diseases project was provided by the NIHR (grant number RG65966). E.R.M. acknowledges support from the European Research Council (Advanced Researcher Award), the NIHR (Senior Investigator Award and Cambridge NIHR Biomedical Research Centre), the Cancer Research UK Cambridge Cancer Centre, and the Medical Research Council (Infrastructure Award). The University of Cambridge has received salary support for E.R.M. from the National Health Service (NHS) in the East of England through the Clinical Academic Reserve. The views expressed herein are those of the authors and not necessarily those of the NHS or the Department of Health. D.G.E. is an NIHR Senior Investigator and is supported by the NIHR Manchester Biomedical Research Centre.